Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 11Neoplasm Metastasis 3Lung Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Thymoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Gastroesophageal Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Clinical Stage IVB Gastric Cancer AJCC v8 1Clinical Stage III Gastric Cancer AJCC v8 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Brain Neoplasms 1

Interventions

Fluorouracil 41Radiotherapy 38Cisplatin 35Oxaliplatin 32Leucovorin 24Paclitaxel 22Irinotecan 20Docetaxel 17Neoadjuvant Therapy 14Carboplatin 13Radiation 12Capecitabine 12Surgical Procedures, Operative 10Cetuximab 8Biopsy 8durvalumab 7Gefitinib 7Chemotherapy, Adjuvant 7tremelimumab 6pembrolizumab 6Nivolumab 6Magnetic Resonance Spectroscopy 6Folfox protocol 6Taxes 5Immunohistochemistry 5Endoscopy 5Gene Expression Profiling 4Epirubicin 4Drug Therapy 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma Of Esophagus × Ramucirumab × Clear all
NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT03995017 2023-02-01

RiME

University of Kansas Medical Center

Phase 1/2 Unknown
34 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡